E Ink Corporation

A123 Systems LLC

Eyeon Particle Sciences LLC

Particle Sciences, Inc.

Massachusetts Institute of Technology

Calm Water Therapeutics LLC

Chemo Research, S.l.

Neurelis, Inc.

Hale Biopharma Ventures, LLC

Children's Medical Center Corporation

Clearink Displays, Inc.

Andrew L Loxley

Mark Mitchnick

Libing Zhang

Jonathan D Albert

Paul Stephen Drzaic

Joseph M Jacobson

Ian D Morrison

Eugene Rex Cooper

Antoni S Gozdz

Richard K Holman

Michael L Steiner

Barrett Comiskey

Karl Raymond Amundson

Barrett O Comiskey

Garry Thomas Gwozdz

Yet-Ming Chiang

Gilbert N Riley, Jr

Michael S Viola

Glen Crossley

Richard J Paolini, Jr

Gregg Michael Duthaler

Edward T Maggio

Robert Waverly Zehner

Richard M Webber

Thomas Henry Whitesides

Charles Howie Honeyman

David Darrell Miller

Craig A Herb

Robert L Lee

Russell J Wilcox

Robert David Feeney

David Maxwell Kleinman

Steve Cartt

David F Hale

David Medeiros

William Douglas Moorehead

Katharine Geramita

Ronnie Wilkins

David Fairhurst

Mavyn M Holman

Kimberly L Houde

John E Ritter

Lan Cao

Justin J Abramson

Celestino Ronchi

Peter J Valianatos

Gonzalo Hernández Herrero

Tibyron Quinn

Peter K Wagner

Anthony Edward Pullen

Alexi Arango

John N Kheir

Bram M Sadlik

Anthony E Pullen

Michele L Ostraat

Boon Ng

Ismar Dizdarevic

Christy Ann Eatmon

Katherine Geramita

Benjamin Nunes

Lindsay Thomson

Abhijit Gokhale

David Hale

Robert Feeney

The invention contemplates a copolymer which is a graft or block copolymer useful to change wettability and surface characteristics of biological surfaces. Methods for use of these formulations and coatings to change wettability and sterically stabilize, and lubricate biological surfaces in a subject, for example, in the treatment of dry eye syndrome, and to prevent adherence of unwanted proteins, for example in the treatment of contact lens intolerance, are provided.

Bi-functional co-polymer use for ophthalmic and other topical and local applications

The invention relates to pharmaceutical compositions comprising one or more benzodiazepine drugs for nasal administration, methods for producing and for using such compositions.

Administration of benzodiazepine compositions

Aqueous dispersions of chemically and physically stable particles for use in delivery of active pharmaceutical ingredients and processes for their production and use to enhance a biological response to an active pharmaceutical ingredient and prophylactically or therapeutically treat a subject are provided. Vaccines, wherein the active pharmaceutical ingredient is a solution of subunit vaccine antigen mixed with a colloidal dispersion of electrically charged particles and use of such vaccines in immunization are also provided.

Particle formulations and uses thereof

The invention contemplates a copolymer which is a graft or block copolymer useful to change the ocular surface temperature and other characteristics of biological or contact lens surfaces. Methods for use of these formulations and coatings to increase the temperature of the skin, mucous membranes, eye or eyelids will help treat many conditions including blepharitis and non-healing ulcers. Methods to decrease evaporation, improve wettability and stabilize the tear film, and lubricate biological surfaces in a subject, for example, in the treatment of dry eye syndrome, and to improve contact lens tolerability, are provided.

A targeted drug delivery complex containing a particle, a targeting moiety electrostatically attached to the particle, and an active pharmaceutical ingredient attached to or dispersed or dissolved within the particle is provided. Also provided are pharmaceutical formulations containing a plurality of the complexes as well as methods for use in targeting an active pharmaceutical ingredient to a selected cell or tissue and production of such formulations.

Drug delivery particle formulations with targeting moieties

Formulations containing a carrier and microbubbles encapsulating oxygen gas, and methods for making and using the formulations are described herein. The formulations are manufactured by a process which includes high shear homogenization. The resulting microbubble suspension may be centrifuged to further concentrate the microbubbles. The resulting concentrated LOM suspension preferably has an oxygen content ranging from 50 to 99% (vol). Prior to administration to a patient, the viscosity of the LOM suspension may be reduced to the desired viscosity, preferably similar to the viscosity of the patient's blood. The resulting LOM formulation typically has an oxygen concentration ranging from 65 to 80% (vol). The microbubbles are formed from one or more lipids, preferably one or more phospholipids, most preferably DSPC, and preferably also contain one or more stabilizing agents/excipients, preferably cholesterol.

Process for forming microbubbles with high oxygen content and uses thereof

Delivery devices of a degradable or nondegradable biocompatible matrix with one or more encapsulated active pharmaceutical ingredients or one or more particle-bound active pharmaceutical ingredients dispersed in the matrix are provided. Also provided are methods for delivering an active pharmaceutical ingredient to a subject with these delivery devices. Modified vaginal rings are also provided as well as surface coatings for delivery devices which minimize bio-interaction of the coated delivery devices.

Delivery devices containing encapsulated and/or practice-bound active pharmaceutical ingredients

Improvements and modifications are provided in the type of frustrated total internal reflection (TIR) systems described in U.S. Pat. Nos. 6,885,496; 6,891,658; 7,286,280; 7,760,417 and 8,040,591. The improvements and modifications include various methods to improve display operation of hemispherical beaded front plane TIR systems such as (a) inhibit or prevent the undesired non-uniform distribution and lateral migration of charged, electrophoretically mobile, TIR frustrating particles by encapsulating or tethering the particles to the beaded front plane surface; (b) inhibit or prevent the settling of the TIR frustrating particles such as modifying the viscosity of the low refractive index medium; and (c) inhibit or prevent the non-uniformity of the applied electric field during display operation such as using a conforming rear electrode.

TIR-modulated wide viewing angle display

It relates to a device comprising (a) a core comprising polyurethane; (b) a sheath comprising ethylene vinyl acetate copolymer, said sheath substantially or completely surrounding said core; and (c) one or more active pharmaceutical ingredients dissolved or dispersed in said core and/or said sheath; and to a process for its preparation.

Core sheath drug delivery devices

Growing community of inventors

Roslindale, MA, United States of America

Andrew L Loxley